An unparalleled track record

The breadth of expertise within our organisation, the diversity of our partners and our unparalleled five-year track record of achievement as a pioneer in Europe uniquely positions EPEMED to credibly advance the harmonization of practices and broad introduction of PM across Europe’s health systems.


  • 3rd international conference in Luxembourg in October and release of the first results of the EPEMED La Charité european patient access study, in the presence of 120 representatives of national governments, European institutions, industry, academia and prestigious research panels
  • Numerous collaborations with other European organisations: EuroBioForum, EBE- EFPIA, EDCA, EuroMeDiag Eurobiomed, CRP Santé, BioM Biotech Cluster Development GmbH and of course La Charité
  • Programmatic committees deployed a fantastic dynamic
  • EPEMED was represented at 13 conferences in Europe and cross border


  • Relocation of EPEMED offices to Luxembourg to add to the efforts of the Grand Duchy in developing a cluster around Personalised Medicine
  • Strengthening of EPEMED strategic development not only with the appointment of a General Delegate but also with its board expansion to new members
  • Launch of three Programmatic Committees formed and chaired by our members covering regulation, education and health economic policy and reimbursement
  • Organization of 3 webinars held by distinguished panelists addressing key issues shaping the Personalised Medicine space
  • EPEMED partnered with La Charité Institut für Sozialmedizin, Epidemiologie und Gesundheitsokonomie in Berlin to launch a major market access study, which will on completion, end of 2013, be considered as a seminal work on Personalised Medicine patients access in Europe


  • Organisation of 2 Webinars
  • Publication of a 1st White Paper “Market access challenges in the EU for high medical value diagnostic tests”
  • Publication of the proceedings of the 2010 international conference
  • Chairing of a morning session at the “European Perspectives in Personalised Medicine” conference organised by the European Commission and held in Brussels in May
  • 2nd international conference in Luxembourg in December: “Personalised Medicine in Europe, what will it take to succeed? More than 160 attendees enjoyed a successful and informative conference with prestigious speakers


  • 1st international conference at the French Senate “Personalised Medicine in France and in Europe: a major health economic challenge”


  • Creation with international key opinion leaders: Alain Huriez (Chairman and founder), Werner Kroll (Novartis), Mara Aspinall (Ventana Roche), Vincent Fert (Ipsogen), Iain Miller (Healthcare Strategies Group)